Company · Healthcare · AI
Every investor coverage indicates participated in a round OpenEvidence raised.
Companies OpenEvidence acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming OpenEvidence. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Fidji Simo, who left OpenAI to cofound ChronicleBio, which has raised $20 million to use AI and biological data to subtype chronic illnesses like POTS and long COVID and rescue shelved drugs.
Blackbird's post explaining its participation in Baseten's $1.5 billion Series F, its biggest investment yet, and why inference infrastructure will anchor the open-source AI era; notes rapid growth and senior engineering hires.
Also Dealroom